Opinion|Videos|July 29, 2024
Standard-of-Care Treatment for Patients with LR-MDS
Author(s)Guillermo Garcia-Manero, MD
A medical oncologist discusses standard-of-care treatment practices for patients with lower-risk myelodysplastic syndromes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly discuss a high-level overview of the standard of care (SOC) for patients with LR-MDS.
- How does your treatment decision-making change based on mutational burden (del(5q); SF3B1) and the presence, or not, of ring sideroblasts (RS)?
Advertisement
Related to this article
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Late-Breaking Phase 3 Data Headline ESMO 2026 Presidential Symposium I
2
ESMO 2026 Presidential Symposium II Showcases OS-Improving LBAs in Lung and GI Cancers
3
Key Takeaways From DeLLphi-305 at ESMO 2026
4
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
5